slot ph365

Mannshardt's expertise in statistical methodologies and data science, plus her leadership skills, will further strengthen Westat's capacity to deliver innovative, data-driven solutions to clients. ROCKVILLE, Md. , Nov. 25, 2024 /PRNewswire/ -- Elizabeth Mannshardt , PhD , joined Westat in November 2024 as Vice President and Director, Statistics and Data Science. Mannshardt brings a wealth of statistical and data science knowledge, leadership, and strategic planning to Westat's senior leadership team. She also has strong connections to the broader statistical community, having served in several American Statistical Association (ASA) leadership roles and is an ASA Fellow. Prior to joining Westat, Mannshardt served as the director of the Statistics, Methods, and Innovation Program at the National Center for Science and Engineering Statistics of the National Science Foundation where she led a team of survey statisticians and methodologists. Earlier, she was the acting director of the Information Access and Analysis Services Division in the Environmental Protection Agency's Office of Information Management where she led a team of data scientists and information technologists managing national and public-facing programs and services, including the design and buildout of the agency's cloud-hosted data management and analytics platform. Mannshardt is an adjunct associate professor in North Carolina State University's Department of Statistics and vice chair of ASA's Membership Council, which provides oversight and guidance to nine ASA committees. "Liz's extensive expertise in statistics and data science, along with her outstanding leadership and strategic foresight, will continue to drive our capacity to deliver cutting-edge, data-driven solutions," says Jeri Mulrow , MS , Vice President and Sector Lead, Data Solutions. "Her strong ties within the statistical profession and her dedication to collaboration will further elevate our organization." About Westat ( www.westat.com ) Westat is a leader in research, data collection and analysis, technical assistance, evaluation, and communications. Our evidence-based findings help clients in government and the private sector accelerate advancements in health, education, transportation, and social and economic policy. Since 1963, our dedication to improving lives through research and our approach to projects grounded in investigative curiosity, equity, statistical and data rigor, adaptive methods, and advanced technology are why clients find exceptional value in our work. View original content to download multimedia: https://www.prnewswire.com/news-releases/elizabeth-mannshardt-joins-westat-as-vp-and-director-statistics-and-data-science-302315620.html SOURCE WestatFirst Citizens: Higher Buyback Momentum Is Welcome, But Valuations Are Not Ideal

Inside Team Trump’s Big Bet On Election Integrity — And How It Paid Off

WuKong Education Named to the 2025 GSV 150 for Leading the Way in Education TechnologyThe expanded Big Ten is poised to be a major player in this season's College Football Playoff. The 18-team conference had three of the top-four teams in the AP poll this week — No. 1 Oregon, No. 2 Ohio State and No. 4 Penn State. A one-loss Indiana team is ranked 10th but is still very much a contender to make the playoff, given how many Southeastern Conference teams have three defeats or more. Indiana's rise has been perhaps the Big Ten's biggest story this season. Much of the spotlight was on newcomers Oregon, Southern California, UCLA and Washington, but aside from the top-ranked Ducks, that foursome has struggled to impress. Meanwhile, the Hoosiers won their first 10 games under new coach Curt Cignetti before losing at Ohio State last weekend. Oregon beat Ohio State 32-31 back in October, and if the Buckeyes beat rival Michigan this weekend, they'll earn a rematch with the Ducks for the Big Ten title. And it's entirely possible another matchup between those two teams awaits in the CFP. Dillon Gabriel has quarterbacked Oregon to an unbeaten record, throwing for 3,066 yards and 22 touchdowns in 11 games. But don't overlook Iowa's Kaleb Johnson and his 21 rushing TDs, and quarterback Kurtis Rourke has been a big part of Indiana's improvement. Penn State's Abdul Carter has eight sacks and two forced fumbles and could be one of the top edge rushers drafted this year. Oregon (11-0, 8-0), Ohio State (10-1, 7-1), Penn State (10-1, 7-1), Indiana (10-1, 7-1), Illinois (8-3, 5-3), Iowa (7-4, 5-3), Michigan (6-5, 4-4), Minnesota (6-5, 4-4), Washington (6-5, 4-4), Southern California (6-5, 4-5), Nebraska (6-5, 3-5) and Rutgers (6-5, 3-5) have already reached the six-win mark for bowl eligibility. Michigan State (5-6, 3-5) and Wisconsin (5-6, 3-5) can join them. There may not be many firings in general at the top level of college football. The prospect of sharing revenue with athletes in the future might lead schools to be more judicious about shedding one coach and hiring a new one. Who should be most worried in the Big Ten? Well, Lincoln Riley is struggling to stay above .500 in his third season at USC. Purdue is 1-10, but coach Ryan Walters is only in his second season. Maryland's Mike Locksley has been there six years and his Terrapins are 4-7, but this was his first real step backward after guiding the team to three straight bowl wins. Cignetti has shown it is possible for a coaching change to push a previously moribund program to some impressive heights in a short amount of time — but the improvement has been more incremental at Michigan State following Jonathan Smith's arrival. Sherrone Moore wasn't a completely unknown commodity at Michigan after he won some massive games in place of a suspended Jim Harbaugh last year. But in his first season completely at the helm, the Wolverines have declined significantly following their national title a season ago. The Big Ten is home to one of the most dynamic freshmen in the country in Ohio State receiver Jeremiah Smith. He has 52 catches for 899 yards and nine touchdowns. Highly touted quarterback Dylan Raiola has teamed up with fellow freshman Jacory Barney (49 catches) to lead Nebraska to bowl eligibility. Ohio State is on track to land the Big Ten's top class, according to 247 Sports, but the big news recently was quarterback Bryce Underwood flipping from LSU to Michigan. If the Wolverines do in fact keep Underwood in his home state, that would be a big development for Moore. Be the first to know Get local news delivered to your inbox!

TikTok video shows burning of ‘TRUMP,’ ‘USA’ into Glen Burnie road

Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockSpecial counsel asks judge to dismiss subversion case against TrumpOmg! See what FUGUS student who graduated with first class said was his major challenges in school

State Administration Council Vice-Chairman Deputy Prime Minister Vice-Senior General Soe Win delivered a speech at the work coordination meeting 5/2024 of the Illegal Trade Eradication Steering Committee at the Ministry of Commerce in Nay Pyi Taw yesterday. Speaking at the meeting, the Vice-Senior General, who is also the committee chairman, said after the 17th coordination meeting of the committee, a total of 560 decisions were made and implemented until the 16th meeting. Effective actions should be taken to combat the illegal trade as it causes losses to consumers and local business people. Moreover, illegal trade can cause revenue losses for the country. There is the cost of illegal trade combatting activities. In the local production sector, the imported substandard raw materials can make products of low quality for the local entrepreneurs. Moreover, it can be harmful to the local consumers and substandard products in the international market, and the market share of the country can be affected seriously. Fake and substandard raw materials imported from foreign countries without any guarantees can affect the local production sector and cause losses. Moreover, illegal trading in various forms can affect the economic growth of the country and receivable revenues like commercial tax, income tax and special commodities tax, and show a decline in the GDP of the State. He also stressed the duties of the steering committee, region and state special task forces to crack down on illegal trade effectively and decisively, and the serious consequences of unlawful trade in the economic sector. Every government in the country drafts policies for political, economic and social affairs. The SAC also set the policies in these fields and the ministries, state and region governments, organizations and entrepreneurs should find their proper ways in their respective regions to overcome the limitations and challenges in implementing the economic policy of the country without any delays. He continued that Myanmar is an agriculture-based country, and US$14.641 billion worth of products were exported in the 2023-2024 financial year and the export volume reached US$9.825 billion until November of 2024-2025 financial year. Therefore, the departments concerned should make efforts for the agriculture, livestock and breeding sectors this financial year to develop the export sector. He added that smuggled and illegal commodities worth K379.247 billion were seized in 17,258 cases from January 2022 to November 2024. Concerning seizures in Myanmar, the Vice-Senior General noted that the Customs Department and Mandalay Region stood first for the seizure of smuggled and illegal commodities in September, October and November 2024, followed by the Kayin State and Kachin State. Among them, he continued that unregistered vehicles and illegal commodities were seized as the most enormous volume, followed by intermediate goods and capital goods. Although the monthly seizures show an increase in 2024, the record of export and import data of trading partner countries shows huge gaps when compared with the export and import data of the country. Therefore, the steering committee and special task forces are needed to accelerate their actions four times than before. He then highlighted the instruction of the Prime Minister to double the current export volumes and added that illicit trade brings huge hindrances to the MSMEs and local entrepreneurs in their production sectors. He also pointed out that the people informed 204 illegal trading in September, October and November 2024, of which 79 were false news, four were late news, and 121 were accurate news. A high number of trustworthy news outlets show supportive measures to carry out duties more effectively. A total of K5 billion worth of illegal goods were seized from 242 cases. He urged the MSME entrepreneurs to get rights for their products as the country enacts The Trademark Law, the Industrial Design Law, the Patent Law and the Copyright Law. The responsible agencies should facilitate the application processes and take action against those who break the law. Intellectual Property rights are complicated and can cause transnational crimes. According to the findings of CECD and WIPO, the value of international trade in counterfeit goods was estimated at US$509 billion, the equivalent of three per cent of world trade. He also called for attendees to work together to combat the unlawful trade. After hearing the reports made by the attendees, the Vice-Senior General coordinated all discussions and reports. — MNA/KTZH

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen